Dialysis-Related Amyloidosis Treatment Act of 2025

The Dialysis-Related Amyloidosis Treatment Act of 2025 would expand Medicare coverage and payment rules to explicitly cover treatments for dialysis-related amyloidosis (DRA). It adds DRA treatments to the list of covered items and services under Medicare Part B, defines what counts as a DRA treatment, and requires that payments for these treatments be made separately from standard renal dialysis payments at 100 percent of the reasonable charges. The measure also excludes DRA treatments from being treated as renal dialysis services under the current prospective payment or fee schedules. The changes would take effect on the date of enactment. In practical terms, if a patient receives an FDA-approved treatment for DRA in a dialysis facility, Medicare would cover the treatment separately from the regular dialysis payment, and providers would be reimbursed at 100% of what is reasonably charged. This aims to improve access to approved therapies for patients suffering from DRA and to clarify how these treatments are billed and paid for under Medicare.